UNIVERSITY COLLEGE DUBLIN; NATIONAL UNIVERSITY OFIRELAND; DUBLIN
发明人:
CHRIS WATSON,JOHN BAUGH,MARK LEDWIDGE,KEN MCDONALD
申请号：
GB201309444
公开号：
GB2514424A
申请日:
2013.05.25
申请国别(地区):
GB
年份:
2014
代理人:
摘要：
Hypomethylating agents may be used for the prevention or treatment of cardiomyopathies, and in particular hypertrophic cardiomyopathy. The hypomethylating agents may comprise 5-Azacytidine or 5-Aza-2-Deoxycytidine, or other agents which inhibit the expression or action of DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3A (DNMT3A), or DNA methyltransferase 3B (DNMT3B), such as siRNA molecules directed against these genes. In addition, agents which reduce the expression of, silence or degrade hypoxia inducible factor (HIF) protein or mRNA may be used for the prevention or treatment of cardimyopathy or myocardial fibrosis. Screening methods for identifying an agent capable of preventing or treating cardiomyopathy comprise testing the ability of the agents to modify expression and/or action of one or more of the following genes: MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1, CSRP3, TTN, ACTN2, MYH6, TCAP, TNNC1, ACTA1, and in particular MYBPC3 or ACTA1.
